Clinical trials
Prostate Cancer (Adenocarcinoma) clinical trials
Below are recruiting prostate cancer (adenocarcinoma) clinical trials, each written for real people, not researchers. We’re tracking 549 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06202820Recruiting
Heart health monitoring for men on hormone therapy
This study checks how men starting hormone therapy (ADT) for prostate cancer are doing with their heart health. It offers follow-up visits at the cancer center to track blood pressure and lab results, with the goal of catching any heart-related issues early.
Boston, MassachusettsAges 18 years+ - NCT05647564Recruiting
PET/CT scan to study why prostate cancer resists treatment
This study uses a PET/CT scan to learn how and why prostate cancer becomes resistant to treatment. It may help researchers better match future therapy choices for people whose prostate cancer is progressing.
Madison, WisconsinAges 18 years+ - NCT04363164RecruitingPhase 2
Testosterone then enzalutamide to stop prostate cancer spread
This Phase 2 trial tests whether giving testosterone first, then enzalutamide (a prostate cancer hormone-blocking pill), can slow or prevent worsening metastatic prostate cancer. It is designed for men whose cancer progressed despite ongoing hormone-suppression treatment.
San Diego, CaliforniaAges 18–90 - NCT07288359RecruitingPhase 1/Phase 2
Study of GVV858 for HR+/HER2- breast cancer and other solid tumors
This trial is testing a new drug, GVV858, either alone or with hormone therapy, for people with HR+/HER2- advanced breast cancer or certain other advanced solid tumors. It may be an option if standard treatments are no longer working or available.
Atlanta, GeorgiaAges 18 years+ - NCT06177093Recruiting
Higher dose prostate radiation with MRI guidance
This study tests a higher dose of radiation for prostate cancer using an MRI-guided machine (MR-Linac). It aims to see if a more targeted dose can be safely given to the tumor while protecting healthy tissue.
Toronto, OntarioAges 18 years+ - NCT03417336Recruiting
Radiation for prostate cancer using smaller, targeted doses
This trial studies a specific radiation schedule for prostate cancer (with an extra “boost” dose) and checks whether it works well and is tolerable. It may help people with higher-risk, localized prostate cancer by aiming at the cancer while limiting side effects to surrounding tissues.
DijonAges 18–85 - NCT06825091RecruitingPhase 3
Comparing new SBRT to standard radiation for prostate cancer
This trial compares a newer, more precise type of radiation (adaptive SBRT) with standard image-guided radiation for prostate cancer. It aims to see if the newer approach is better at targeting the tumor while reducing side effects.
Toronto, OntarioAges 18 years+ - NCT03861676RecruitingEarly Phase 1
PET-guided targeted radiation for early prostate cancer
This early-phase study tests a precise, targeted radiation treatment for prostate cancer, using a special PET scan to help plan exactly where to treat. It may help reduce the amount of radiation to surrounding tissues while treating the cancer.
Baltimore, MarylandAges 18–100 - NCT07142551RecruitingPhase 2
Testosterone priming with darolutamide for metastatic prostate cancer
This trial tests whether giving a high dose of testosterone before standard hormone therapy can help the treatment work longer for men with prostate cancer that has spread. You would receive testosterone injections for a short time, then a hormone blocker (darolutamide) along with continued testosterone shots.
Baltimore, MarylandAges 18 years+ - NCT06126731RecruitingPhase 1/Phase 2
Antibiotics plus enzalutamide for advanced prostate cancer
This trial tests whether adding specific antibiotics (amoxicillin, metronidazole, vancomycin, ciprofloxacin) to enzalutamide can help treat advanced prostate cancer that has stopped responding to other treatments. It aims to see if changing gut bacteria can make the cancer therapy work better.
BellinzonaAges 18 years+ - NCT05176483RecruitingPhase 1
New drug combinations for advanced solid tumors
This trial tests a new drug called zanzalintinib, which may slow or shrink various types of advanced cancer. It is given together with other cancer treatments, and the study is looking at many different cancers including kidney, prostate, bladder, lung, liver, and more.
Phoenix, ArizonaAges 18 years+ - NCT04615013RecruitingPhase 1
NBTXR3 with chemoradiation for esophageal cancer treatment
This early-phase study tests adding NBTXR3 (a special treatment given into the tumor) to standard chemotherapy and radiation for esophageal cancer. The goal is to see if it can improve cancer control and to learn about safety and dosing.
Houston, TexasAges 18 years+ - NCT06066437RecruitingPhase 1/Phase 2
Lutetium before prostate surgery for high-risk cancer
This trial tests a radioactive drug (lutetium) given before surgery to men with high-risk prostate cancer that hasn't spread. The goal is to see if it can shrink the tumor and improve outcomes.
Houston, TexasAges 18 years+ - NCT07550517RecruitingPhase 2
Radiation plus experimental nuclear medicine for high-risk prostate cancer
This trial tests whether adding an experimental radioactive drug called PSMA-617 to standard radiation and hormone therapy helps men with high-risk prostate cancer that hasn't spread beyond the pelvis. The radioactive drug targets cancer cells specifically.
Baltimore, MarylandAges 18 years+ - NCT06922318RecruitingPhase 2
Combined suppression of MYC for advanced prostate cancer
This trial tests a new combination of drugs (ZEN-3694 and enzalutamide) for men with advanced prostate cancer that has stopped responding to standard hormonal treatments. It aims to see if this combination can help slow or stop the cancer from growing.
Baltimore, MarylandAges 18 years+ - NCT07335224Recruiting
Acupuncture for hot flashes in men with prostate cancer
This trial tests if acupuncture can reduce the daily discomfort from hot flashes caused by hormone therapy (androgen deprivation therapy) for prostate cancer. It may help men who are bothered by frequent or intense hot flashes find better relief.
Fairfax, VirginiaAges 18 years+ - NCT07226986RecruitingPhase 1/Phase 2
Study of AMO959 with Lutetium-177 and ARPI for prostate cancer
This trial tests a new combination therapy for men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. It combines an experimental drug (AMO959) with a targeted radiation treatment (Lutetium-177) and a standard hormone therapy to see if it helps control the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT07711002RecruitingPhase 3
Saruparib with standard therapy for metastatic hormone-sensitive prostate cancer
This trial tests a new drug called saruparib, which may help keep prostate cancer from growing. It is for men whose cancer has spread and who have already received certain treatments. The study combines saruparib with a standard hormone therapy to see if it works better than the hormone therapy alone.
Hot Springs, ArkansasAges 18 years+ - NCT06855277RecruitingPhase 3
AAA817 with hormone therapy for advanced prostate cancer
This trial tests a new combination treatment (AAA817 plus a hormone therapy) against standard care for men with advanced PSMA-positive prostate cancer that has spread and stopped responding to a previous hormone therapy. It may be an option if you haven't had certain prior treatments.
Homewood, AlabamaAges 18–100 - NCT02865330Recruiting
Registry study for men on active surveillance for low-risk prostate cancer
This is a registry study that follows men with low-risk prostate cancer who choose active surveillance instead of immediate treatment. It helps doctors understand how safe and effective active surveillance is, including confirming results with repeat biopsies.
ValenciaAges 18–80 - NCT05956639RecruitingPhase 3
Rezvilutamide with ADT and chemo: shorter versus longer treatment
This Phase 3 trial compares two lengths of rezvilutamide treatment when given with hormone therapy (ADT) and chemotherapy for men with advanced prostate cancer. It aims to find which treatment duration works best and is safest to help control the cancer.
Nanjing, JiangsuAges 18 years+ - NCT06177015RecruitingPhase 3
Darolutamide with chemo for metastatic prostate cancer
This trial tests a new way of using darolutamide (a hormone therapy) together with standard chemotherapy (docetaxel) and hormone therapy (ADT) for men with prostate cancer that has spread. The goal is to see if taking darolutamide on an intermittent schedule works as well as continuous treatment.
Nanjing, JiangsuAges 40–80 - NCT06330909Recruiting
Focused radiation boost for prostate cancer
This trial tests a newer, more precise radiation treatment that gives a higher dose to the main tumor while keeping radiation to the rest of the prostate the same. It is for men with intermediate- or high-risk prostate cancer who haven't had prior prostate radiation or removal.
Freiburg im Breisgau, Baden-WurttembergAges 18 years+ - NCT06350825RecruitingPhase 3
Surgery plus hormone therapy for advanced prostate cancer
This study tests if removing the prostate and giving strong hormone therapy works better than hormone therapy alone for men whose prostate cancer has spread. It aims to improve how long patients live without the cancer worsening.
Nanjing, JiangsuAges 18–75
Hear when a new Prostate Cancer (Adenocarcinoma) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostate cancer (adenocarcinoma)?
- Yes. Clin2 currently lists 549 recruiting prostate cancer (adenocarcinoma) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostate cancer (adenocarcinoma) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostate cancer (adenocarcinoma) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.